克感利咽口服液抗冠状病毒的实验研究

目的研究克感利咽口服液体内、外抗冠状病毒的作用。方法接种非SARS冠状病毒中华株ZHZ(HK3D3)于人肺K1二倍体细胞(HEL),观察克感利咽口服液体外抗非SARS冠状病毒中华株ZHZ(HK3D3)的作用;以鸡传染性支气管炎病毒(IBV)建立动物体内冠状病毒模型,筛选易感鸡种,诱其发病。以雏鸡的死亡率、死亡保护率及病理变化为指标,观察克感口服液体内抗鸡传染性支气管炎病毒(鸡冠状病毒)的作用。结果体外实验:克感利咽口服液的半数毒性浓度为32g/L,在其最高稀释浓度0.156g/L下,仍可以抑制病毒。体内实验:克感利咽口服液预防及治疗实验的死亡保护率分别为35.1%和26.50%,未见显著性差异。结论克感利咽口服液体内未见抗冠状病毒作用,但能一定程度上改善病毒感染引起的呼吸道症状;体外则有明显的抗非SARS冠状病毒作用,显示了一定的开发前景。

An Experimental Study on Kegan Liyan Oral Liquid for Counteracting Coronavirus

Objective To Study the Kegan Liyan Oral Liquid(KLOL)for counteracting coronavirus in vivo and vitro. Methods HK3D3 was inoculated into HEL cell,and then the effect of KLOL for counteracting non-SARS coronavirus was evaluated;The internal coronavius animal models were established with infective bronchitis virus (IBV). The susceptible chicken was screened out,infected the chicken to induce morbidity .The mortality,protective rate of mortality and pathogenic changes were observed .Results In-vitro test: The TD50 of KLOL is 32 g/L,and KLOL at MIC being 0.156 g/L can also inhibit the virus. In-vivo test : The mortality was 35.1 %and preventive rate 26.50%,the difference was insignificant . Conclusion KLOL exerts no effect on counteracting coronavius in vivo,but it can relieve respiratory symptoms. KLOL has marked in-vitro effects for non-SARS,and its therapeutic mechanism needs further study.